Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Systematic Development and Verification of A Physiologically-Based Pharmacokinetic Model of Rivaroxaban.

Cheong EJY, Teo DWX, Chua DXY, Chan ECY.

Drug Metab Dispos. 2019 Sep 10. pii: dmd.119.086918. doi: 10.1124/dmd.119.086918. [Epub ahead of print]

2.

Rivaroxaban With and Without Amiodarone in Renal Impairment.

Cheong EJY, Goh JJN, Hong Y, Kojodjojo P, Chan ECY.

J Am Coll Cardiol. 2018 Mar 27;71(12):1395-1397. doi: 10.1016/j.jacc.2018.01.044. No abstract available.

3.

The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat.

Yip LY, Aw CC, Lee SH, Hong YS, Ku HC, Xu WH, Chan JMX, Cheong EJY, Chng KR, Ng AHQ, Nagarajan N, Mahendran R, Lee YK, Browne ER, Chan ECY.

Hepatology. 2018 Jan;67(1):282-295. doi: 10.1002/hep.29327. Epub 2017 Nov 19.

PMID:
28646502
4.

Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.

Cheong EJ, Goh JJ, Hong Y, Venkatesan G, Liu Y, Chiu GN, Kojodjojo P, Chan EC.

Drug Metab Dispos. 2017 Mar;45(3):260-268. doi: 10.1124/dmd.116.073890. Epub 2017 Jan 4.

PMID:
28053220
5.

A strategy based on nucleotide specificity leads to a subfamily-selective and cell-active inhibitor of N6-methyladenosine demethylase FTO.

Toh JDW, Sun L, Lau LZM, Tan J, Low JJA, Tang CWQ, Cheong EJY, Tan MJH, Chen Y, Hong W, Gao YG, Woon ECY.

Chem Sci. 2015 Jan 1;6(1):112-122. doi: 10.1039/c4sc02554g. Epub 2014 Sep 22.

6.

T-type Ca2+ channels as therapeutic targets in the nervous system.

Shin HS, Cheong EJ, Choi S, Lee J, Na HS.

Curr Opin Pharmacol. 2008 Feb;8(1):33-41. doi: 10.1016/j.coph.2007.12.003. Epub 2008 Jan 18. Review.

PMID:
18203662
7.

Factors affecting somatic embryogenesis in Prunus incisa cv. February Pink.

Cheong EJ, Pooler MR.

Plant Cell Rep. 2004 Jun;22(11):810-5. Epub 2004 Mar 12.

PMID:
15022015

Supplemental Content

Loading ...
Support Center